Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11041MR)

This product GTTS-WQ11041MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11041MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3103MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ2273MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ10599MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ805MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ12343MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ1867MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8393MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW